News
Apr 27, 2026
DUBLIN - The U.S. Food and Drug Administration has granted Fast Track Designation to coramitug, an investigational antibody for treating ATTR amyloidosis with…
Apr 27, 2026
Patients enrolled in more recent clinical trials for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) exhibited baseline characteristics consistent with less…
Apr 27, 2026
Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3Coramitug is being evaluated by Novo…
Apr 25, 2026
AbstractBackgroundLarge-scale, nationwide data for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Japan are limited.ObjectivesThis multicenter…
Apr 24, 2026
AbstractTransthyretin (TTR) amyloidosis is a protein misfolding disease characterized by amyloid fibril deposition in vital organs, leading to cardiomyopathy (ATTR-…
Apr 23, 2026
AbstractWild-type transthyretin cardiac amyloidosis (ATTRwt-CM) is increasingly recognized as an underdiagnosed cause of heart failure with preserved ejection…
Apr 22, 2026
Amyloid light chain (AL) cardiomyopathy (AL-CM) is a highly aggressive disease with high early mortality without prompt and effective treatment; however, its low…
Apr 22, 2026
Webinar Session: Wednesday, April 22nd at 6 PM (ET) Zoom Meeting(These sessions will not be recorded due to patient involvement and HIPAA laws)To Register …
Apr 21, 2026
AbstractBackgroundCardiac biomarker complete response (CR) is a new concept in amyloid light chain (AL) cardiac amyloidosis (CA).ObjectivesThe aim of this study was…
Apr 21, 2026
AbstractBackground and AimsEarly detection is important given the availability of new disease-modifying therapies and the high prevalence of transthyretin amyloid…